AXSM

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments. Arrowhead Pharmaceuticals (ARWR) In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Arrowhead Pharmaceuticals, with a price target of $82.00. The company's shares closed last Monday at $28.00, close to its 52-week low of $26.81. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arrowhead-pharmaceuticals-arwr-and-axsome-therapeutics-axsm?utm_source=advfn.com&utm_medium=referral